查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797997

2032 年胚胎胚胎着床前基因检测市场预测：按产品、流程、技术、应用、最终用户和地区进行的全球分析

Preimplantation Genetic Testing Market Forecasts to 2032 - Global Analysis By Product (Reagents & Consumables, Instruments and Software), Procedure, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球胚胎着床前基因检测市场预计在 2025 年达到 8.831 亿美元，到 2032 年将达到 21.033 亿美元，预测期内的复合年增长率为 13.2%。

胚胎着床前基因检测是对透过体外受精 (IVF) 产生的胚胎进行的程序，用于在受孕前识别基因或染色体异常。该程序涉及分析胚胎中的一个或多个细胞，以筛检遗传疾病、染色体正常性或其他遗传疾病。这项检测有助于选择健康的胚胎进行植入，从而降低后代遗传疾病的风险。

根据美国卫生与公众服务部的数据，数百万美国人在一生中的某个阶段都会受到不孕症的影响。试管婴儿（IVF）是治疗不孕症的关键方法，占人工授精的99%以上。

遗传疾病和不孕症增多

全球遗传性疾病和不孕症盛行率的上升是胚胎胚胎着床前基因检测市场的主要驱动力。选择辅助生殖技术的夫妻越来越多地寻求基因筛检，以降低胚胎中遗传性疾病的风险。诊断准确性的提高以及对染色体异常认识的提高进一步推动了这一需求。随着母亲年龄的增长和不孕症的上升，尤其是在都市区，胚胎植入前基因检测 (PGT) 已成为确保健康怀孕的主动解决方案。

高成本且报销政策有限

儘管胚胎胚胎着床前基因检测 (PGT) 具有临床益处，但高成本仍然是其发展的一大障碍，尤其是在新兴经济体。有限的保险覆盖范围和严格的报销政策阻碍了其广泛应用。许多患者面临高昂的自付费用，尤其是在PGT与IVF捆绑治疗的情况下。此外，法律规范的地区差异进一步限制了PGT的可及性。这些经济和政策限制阻碍了市场渗透，尤其是在中等收入者和公共医疗体系中。

体外受精和辅助生殖技术的采用日益增多

体外受精 (IVF) 和其他辅助生殖技术 (ART) 的广泛应用为 PGT 市场创造了巨大的成长机会。随着 IVF 成功率的提高，越来越多的诊所开始整合基因检测，以提高植入成功率并降低流产率。 ART 在同性伴侣、单亲家庭以及反覆流产人群中越来越受欢迎，扩大了其患者群体。人工智慧 (AI) 与次世代定序(NGS) 的整合进一步提高了 PGT 的准确性，吸引了新的人群，并推动了临床成功。

某些人群缺乏意识

人们对胚胎胚胎着床前基因检测 (PGT) 的认知不足，对市场扩张构成了重大威胁，尤其是在农村和欠发达地区。儘管不孕症盛行率不断上升，但误解、社会文化禁忌以及有限的遗传素养仍导致该技术普及率低。此外，患者和医疗保健提供者缺乏关于 PGT 益处和合格标准的教育，阻碍了早期应用。这种认知差距持续延误了及时干预，尤其是在高风险遗传性疾病带原者中，从而限制了市场潜力的充分发挥。

COVID-19的影响：

新冠疫情扰乱了全球生育服务，导致体外受精（IVF）延期，PGT（胚胎植入前基因检测）服务量暂时下降。诊所面临人员短缺、出行限制以及试剂和检测套组供应链中断等问题。然而，疫情过后，生育治疗逐渐復苏，人们对基因健康的关注也随之上升。远端医疗、数位化问诊和远距遗传咨询恢復了患者的参与度，在医疗保健数位化不断提升的背景下，支持PGT服务的再度增长。

试剂和耗材部分预计将成为预测期内最大的部分

由于每个检查週期的需求反覆出现，预计试剂和耗材细分市场将在预测期内占据最大市场占有率。实验室依赖高品质的试剂、探针和套件进行准确的胚胎分析，推动了持续的消费。分子诊断工具和基于NGS的检测的不断进步也增加了对专用试剂的需求。此外，全球试管婴儿（IVF）手术数量的不断增加使得耗材的定期采购成为必要，这使得该细分市场成为诊断供应商的主要收益驱动力。

预计胚胎着床前基因筛检领域在预测期内将出现最高的复合年增长率

预计在预测期内，胚胎着床前遗传学筛检(PGS) 细分市场将呈现最高成长率，这得益于人们对提高体外受精 (IVF) 成功率和预防染色体异常日益增长的需求。 PGS 有助于识别非整倍体和结构重排，从而筛选出具有遗传学可行性的胚胎。随着母亲年龄的增长，尤其是在已开发国家，PGS 的重要性日益凸显。此外，NGS 与自动化分析的整合正在提高筛检通讯协定的效率、准确性和可近性。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场占有率，这得益于不孕症治疗旅游的扩张、不孕症的上升以及辅助生殖技术（ART）应用的日益普及。在医疗基础设施的改善和扶持政策的支持下，印度、中国和日本等国家正经历先进生殖健康服务的激增。此外，日益增长的医疗旅游业和具有竞争力的治疗费用也吸引了许多外国患者。该地区庞大的育龄人口和日益增长的遗传健康意识，正帮助其在市场上占据主导地位。

复合年增长率最高的地区：

预计北美地区在预测期内将实现最高的复合年增长率。这得益于其先进的医疗基础设施、较高的辅助生殖技术 (ART) 普及率以及部分州的优惠报销政策。对个人化生殖解决方案和老年父母早期筛检的强劲需求，推动了胚胎植入前基因检测 (PGT) 的普及。此外，领先的基因组检测公司、清晰的监管体係以及胚胎诊断领域的持续临床创新，也支撑着市场的快速扩张。提升患者意识提升和不孕症教育的倡议也推动了该地区的成长动能。

免费客製化服务

订阅此报告的用户可获得以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球胚胎着床前基因检测市场（按产品）

  • 试剂和耗材
  • 装置
  • 软体

6. 全球胚胎着床前基因检测市场（依程序）

  • 胚胎胚胎着床前基因筛检
  • 胚胎着床前基因诊断

7. 全球胚胎着床前基因检测市场（依技术）

  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 萤光原位杂合技术（FISH）
  • 其他技术

8. 全球胚胎胚胎着床前基因检测市场（依应用）

  • 染色体异常
  • X连锁疾病
  • 胚胎侦测
  • 非整倍体筛检
  • HLA型检测
  • 其他用途

9. 全球胚胎着床前基因检测市场（依最终用户）

  • 不孕不孕治疗中心
  • 医院
  • 诊断中心
  • 研究中心和学术研究机构

第十章全球胚胎着床前基因检测市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer, Inc.
  • CooperSurgical
  • Abbott Laboratories
  • Natera
  • Rubicon Genomics
  • Oxford Gene Technology
  • Yikon Genomics
  • Good Start Genetics
  • Invicta Genetics
  • Progenesis
  • Igenomix
  • Bioarray SL
  • Quest Diagnostics
  • Fulgent Genetics, Inc.
  • Labcorp
  • Genea Limited
Product Code: SMRC30367

According to Stratistics MRC, the Global Preimplantation Genetic Testing Market is accounted for $883.1 million in 2025 and is expected to reach $2103.3 million by 2032 growing at a CAGR of 13.2% during the forecast period. Preimplantation genetic testing is a laboratory procedure performed on embryos created via in vitro fertilization (IVF) to identify genetic or chromosomal abnormalities before pregnancy. It involves analyzing one or more cells from the embryo to screen for inherited diseases, chromosomal normality, or other genetic conditions. This testing helps select healthy embryos for implantation, reducing the risk of genetic disorders in the offspring.

According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures.

Market Dynamics:

Driver:

Increasing incidence of genetic disorders and infertility

The rising global prevalence of genetic disorders and infertility is a primary driver for the preimplantation genetic testing market. Couples opting for assisted reproductive technologies increasingly seek genetic screening to reduce the risk of inherited conditions in embryos. Advancements in diagnostic accuracy and awareness of chromosomal abnormalities have further spurred demand. With maternal age on the rise and infertility rates escalating, particularly in urban populations, PGT is emerging as a proactive solution to ensure healthy pregnancies.

Restraint:

High cost and limited reimbursement policies

Despite its clinical benefits, the high cost of preimplantation genetic testing remains a significant barrier, especially in developing economies. Limited insurance coverage and restrictive reimbursement policies discourage widespread adoption. Many patients are burdened with out-of-pocket expenses, particularly when PGT is bundled with in-vitro fertilization. Moreover, variability in regulatory frameworks across regions further constrains access. These financial and policy constraints hinder market penetration, particularly among middle-income demographics and public healthcare systems.

Opportunity:

Growing adoption of IVF and assisted reproductive technologies

Widespread adoption of in-vitro fertilization (IVF) and other assisted reproductive technologies (ART) presents a strong growth opportunity for the PGT market. As success rates of IVF improve, clinics increasingly integrate genetic testing to enhance implantation outcomes and reduce miscarriages. Rising acceptance of ART among same-sex couples, single parents, and those with recurrent pregnancy loss has broadened the patient base. The integration of AI and next-generation sequencing (NGS) further enhances PGT accuracy, attracting newer demographics and boosting clinical success.

Threat:

Lack of awareness in certain populations

Inadequate awareness regarding preimplantation genetic testing, particularly in rural and underdeveloped regions, poses a critical threat to market expansion. Misconceptions, socio-cultural taboos, and limited genetic literacy reduce adoption rates despite increasing infertility cases. Additionally, lack of education among patients and healthcare providers about the benefits and eligibility criteria of PGT hinders early consultation. This awareness gap continues to delay timely intervention, particularly among high-risk carriers of genetic diseases, curbing the market's full potential.

Covid-19 Impact:

The COVID-19 pandemic disrupted fertility services globally, leading to postponed IVF cycles and a temporary decline in PGT procedures. Clinics faced staff shortages, mobility restrictions, and supply chain interruptions for reagents and test kits. However, post-pandemic recovery has been marked by a rebound in fertility treatments and increased emphasis on genetic health. Telemedicine, digitized consultations, and remote genetic counseling have helped restore patient engagement, supporting renewed growth in PGT services amid strengthened healthcare digitization.

The reagents & consumables segment is expected to be the largest during the forecast period

The reagents & consumables segment is expected to account for the largest market share during the forecast period, due to its recurring demand across every testing cycle. Laboratories rely on high-quality reagents, probes, and kits for accurate embryo analysis, driving consistent consumption. Continuous advancements in molecular diagnostic tools and NGS-based testing have also increased demand for specialized reagents. Additionally, the growing volume of IVF procedures globally necessitates regular procurement of consumables, making this segment a critical revenue driver for diagnostic suppliers.

The preimplantation genetic screening segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the preimplantation genetic screening segment is predicted to witness the highest growth rate, impelled by the growing desire to improve IVF success rates and prevent chromosomal abnormalities. PGS aids in identifying aneuploidy and structural rearrangements, enabling the selection of genetically viable embryos. As maternal age rises, especially in developed nations, the relevance of PGS continues to grow. Additionally, the integration of NGS and automated analytics is enhancing efficiency, accuracy, and accessibility of screening protocols.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding fertility tourism, rising infertility rates, and increased ART adoption. Countries like India, China, and Japan are witnessing a surge in advanced reproductive services, backed by improving healthcare infrastructure and supportive policies. In addition, growing medical tourism and competitive treatment costs attract international patients. The region's large reproductive-age population and rising awareness around genetic health contribute to its dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high adoption of ART, and favorable reimbursement scenarios in select states. Strong demand for personalized reproductive solutions and early screening among older parents bolsters PGT uptake. Furthermore, the presence of leading genomic testing firms, regulatory clarity, and ongoing clinical innovations in embryo diagnostics support rapid market expansion. Patient awareness and fertility education initiatives also enhance regional growth momentum.

Key players in the market

Some of the key players in Preimplantation Genetic Testing Market include Illumina, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Good Start Genetics, Invicta Genetics, Progenesis, Igenomix, Bioarray S.L., Quest Diagnostics, Fulgent Genetics, Inc., Labcorp, and Genea Limited.

Key Developments:

In February 2025, Thermo Fisher Scientific expanded its PGT capabilities with an integrated NGS workflow allowing a single sample to be assessed for both PGT-A (aneuploidy) and PGT-M (monogenic disorders) using Ion Torrent technology-offering comprehensive results with rapid turnaround and accessible analysis tools.

In January 2025, Illumina launched major upgrades to its NovaSeq X Series, including a new single-flow-cell system, advanced software, and improved reagent kits, further strengthening its leadership in genomic sequencing, a key technology for PGT.

Products Covered:

  • Reagents & Consumables
  • Instruments
  • Software

Procedures Covered:

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Technologies Covered:

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Other Technologies

Applications Covered:

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other Applications

End Users Covered:

  • Fertility Centers
  • Hospitals
  • Diagnostic Centers
  • Research Centers & Academic Labs

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preimplantation Genetic Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents & Consumables
  • 5.3 Instruments
  • 5.4 Software

6 Global Preimplantation Genetic Testing Market, By Procedure

  • 6.1 Introduction
  • 6.2 Preimplantation Genetic Screening
  • 6.3 Preimplantation Genetic Diagnosis

7 Global Preimplantation Genetic Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Next Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Fluorescent In-Situ Hybridization (FISH)
  • 7.5 Other Technologies

8 Global Preimplantation Genetic Testing Market, By Application

  • 8.1 Introduction
  • 8.2 Chromosomal Abnormalities
  • 8.3 X-linked Diseases
  • 8.4 Embryo Testing
  • 8.5 Aneuploidy Screening
  • 8.6 HLA Typing
  • 8.7 Other Applications

9 Global Preimplantation Genetic Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Fertility Centers
  • 9.3 Hospitals
  • 9.4 Diagnostic Centers
  • 9.5 Research Centers & Academic Labs

10 Global Preimplantation Genetic Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Illumina, Inc.
  • 12.2 Thermo Fisher Scientific, Inc.
  • 12.3 Agilent Technologies, Inc.
  • 12.4 PerkinElmer, Inc.
  • 12.5 CooperSurgical
  • 12.6 Abbott Laboratories
  • 12.7 Natera
  • 12.8 Rubicon Genomics
  • 12.9 Oxford Gene Technology
  • 12.10 Yikon Genomics
  • 12.11 Good Start Genetics
  • 12.12 Invicta Genetics
  • 12.13 Progenesis
  • 12.14 Igenomix
  • 12.15 Bioarray S.L.
  • 12.16 Quest Diagnostics
  • 12.17 Fulgent Genetics, Inc.
  • 12.18 Labcorp
  • 12.19 Genea Limited

List of Tables

  • Table 1 Global Preimplantation Genetic Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Preimplantation Genetic Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Preimplantation Genetic Testing Market Outlook, By Reagents & Consumables (2024-2032) ($MN)
  • Table 4 Global Preimplantation Genetic Testing Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 5 Global Preimplantation Genetic Testing Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Preimplantation Genetic Testing Market Outlook, By Procedure (2024-2032) ($MN)
  • Table 7 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Screening (2024-2032) ($MN)
  • Table 8 Global Preimplantation Genetic Testing Market Outlook, By Preimplantation Genetic Diagnosis (2024-2032) ($MN)
  • Table 9 Global Preimplantation Genetic Testing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 10 Global Preimplantation Genetic Testing Market Outlook, By Next Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 11 Global Preimplantation Genetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 12 Global Preimplantation Genetic Testing Market Outlook, By Fluorescent In-Situ Hybridization (FISH) (2024-2032) ($MN)
  • Table 13 Global Preimplantation Genetic Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 14 Global Preimplantation Genetic Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 15 Global Preimplantation Genetic Testing Market Outlook, By Chromosomal Abnormalities (2024-2032) ($MN)
  • Table 16 Global Preimplantation Genetic Testing Market Outlook, By X-linked Diseases (2024-2032) ($MN)
  • Table 17 Global Preimplantation Genetic Testing Market Outlook, By Embryo Testing (2024-2032) ($MN)
  • Table 18 Global Preimplantation Genetic Testing Market Outlook, By Aneuploidy Screening (2024-2032) ($MN)
  • Table 19 Global Preimplantation Genetic Testing Market Outlook, By HLA Typing (2024-2032) ($MN)
  • Table 20 Global Preimplantation Genetic Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 21 Global Preimplantation Genetic Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Preimplantation Genetic Testing Market Outlook, By Fertility Centers (2024-2032) ($MN)
  • Table 23 Global Preimplantation Genetic Testing Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global Preimplantation Genetic Testing Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 25 Global Preimplantation Genetic Testing Market Outlook, By Research Centers & Academic Labs (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.